CAS 1537187-53-3

CarfilzoMib-d8

Description:

Carfilzomib-d8 is a deuterated form of Carfilzomib, a selective proteasome inhibitor primarily used in the treatment of multiple myeloma. The deuteration (indicated by the "d8") refers to the incorporation of deuterium, a stable isotope of hydrogen, which can enhance the stability and pharmacokinetic properties of the compound. Carfilzomib works by inhibiting the proteasome, a cellular complex responsible for degrading ubiquitinated proteins, thereby leading to the accumulation of pro-apoptotic factors and ultimately inducing apoptosis in cancer cells. The chemical structure of Carfilzomib-d8 retains the core features of the parent compound, including its ability to bind selectively to the active site of the proteasome. This modification may also facilitate studies in metabolic pathways and drug interactions due to the distinct mass of deuterated compounds. Overall, Carfilzomib-d8 serves as a valuable tool in both therapeutic applications and research settings, particularly in understanding the mechanisms of proteasome inhibition in cancer treatment.

Formula: C₄₀H₅₇N₅O₇

Synonyms:

• (S)-4-Methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-(morpholino-d8)acetamido)-4-phenylbutanamido)pentanamide
• CarfilzoMib-d8
• [2H8]-Carfilzomib

Carfilzomib-d8

CAS: 1537187-53-3

Formula: C₄₀H₄₉D₈N₅O₇

Color and Shape: White To Off-White Solid

Molecular weight: 727.97

Ref: 4Z-C-121002

Carfilzomib-d8

Controlled Product

CAS: 1537187-53-3

Applications Carfilzomib-d8, is the labeled analogue of Carfilzomib (C183460), which is a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.
References Fostier, K., et al.: Oncotargets. Therap., 5, 237 (2012); Geurink, P.P., et al.: J. Med. Chem., 56, 1262 (2013); McCormack, P.L., et al.: Drugs., 72, 2023 (2012);

Formula: C₄₀D₈H₄₉N₅O₇

Color and Shape: Neat

Molecular weight: 727.959

Ref: TR-C183462